Zobrazeno 61 - 70
of 1 913
pro vyhledávání: ''
Autor:
Qiuxia Xiong, Xiulin Jiang, Songqing Fan, Juan Wang, Chuanjiang Chen, Chunyan Xiong, Baiyang Liu, Qingyuan Tao, Hui Zhang, Yong Duan, Lincan Duan, Xiaobo Chen
Publikováno v:
Molecular Medicine Reports
Lung cancer has a high mortality rate worldwide. Non‑SMC condensin I complex subunit H (NCAPH) has been identified to be one of the regulatory subunits of the condensin I complex, which is essential for the correct packaging and segregation of chro
Autor:
Matthew J. Schuchert, Waseem Lutfi, Neil A. Christie, Olugbenga T. Okusanya, Nicholas Baker, Deirdre Martinez-Meehan, James D. Luketich, Rajeev Dhupar
Publikováno v:
Clinical Lung Cancer. 21:349-356
Objectives There is a strong association with improved survival for patients with non–small cell lung cancer (NSCLC) who have developed a pathological complete response (pCR) after neoadjuvant therapy. A national database was used to investigate fa
Autor:
Koji Arihiro, Morihito Okada, Yoshinori Handa, Yoshihiro Miyata, Yasuhiro Tsutani, Yuichiro Kai, Yukio Takeshima, Takahiro Mimae, Noriyuki Shiroma
Publikováno v:
Clinical Lung Cancer. 21:e302-e314
Background The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune mi
Autor:
Eugenia Lamont, Joerg Lindenmann, Alfred Maier, Josef Smolle, Freyja Maria Smolle-Juettner, Udo Anegg, Melanie Fediuk, Christian Porubsky, Nicole Fink-Neuboeck
Publikováno v:
Clinical Lung Cancer. 21:333-340
Introduction Better treatment options entail the risk of multiple tumors in a patient’s lifetime. We studied the incidence, risk factors, and prognostic impact of second primaries and other malignancies in patients with operated non–small-cell lu
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:2231-2239
Adjuvant chemotherapy could improve the prognosis of stage II–III non-small cell lung cancer (NSCLC). However, its influences on stage IB were controversial. The purpose of this study was to investigate whether patients with stage IB NSCLC could be
Autor:
Yoshinobu Saito, Masahiko Kusumoto, Yuichiro Ohe, Masafumi Sata, Kei Sakamoto, Terufumi Kato, Toshimitsu Tokimoto, Reiko Tamura, Tomohisa Baba, Akihiko Gemma, Masatoshi Sugeno, Ou Yamaguchi, Wataru Shimizu, Masahiro Endo, Fumikazu Sakai
Publikováno v:
Japanese Journal of Clinical Oncology
Objective Adverse drug reactions (ADRs) during real-world osimertinib use were investigated in Japan. Methods Patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer treated with second-line or later oral osime
Autor:
Mitchell S. von Itzstein, Yang Xie, Ethan A. Halm, David E. Gerber, Kemp H. Kernstine, Rong Lu, Shidan Wang
Publikováno v:
Cancer Medicine, Vol 9, Iss 12, Pp 4137-4147 (2020)
Cancer Medicine
Cancer Medicine
Background Clinical outcomes for resected early‐stage non‐small cell lung cancer (NSCLC) are superior at high‐volume facilities, but reasons for these differences remain unclear. Understanding these differences and optimizing outcomes across in
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Cancer
BMC Cancer
Background 18 F-FDG is a glucose analogue whose metabolic index SUV can effectively reflect the metabolic level of tumor microenvironment. Aspirin can affect the uptake of 18F-FDG by cancer cells, reducing the SUVmax value of primary tumors, exerting
Autor:
A. Mendes, L. Aguarin, Keith A. Cengel, Gary D. Kao, William P. Levin, Charles B. Simone, Abigail T. Berman, S. Jean-Baptiste, Melissa A. Frick, Stephen M. Hahn, Steven J. Feigenberg, Samuel Swisher-McClure, Jay F. Dorsey, C. Chinniah
Publikováno v:
Clin Cancer Res
Purpose: Although stereotactic body radiotherapy (SBRT) is effective in early-stage non–small cell lung cancer (NSCLC), approximately 10%–15% of patients will fail regionally and 20%–25% distantly. We evaluate a novel circulating tumor cell (CT
Publikováno v:
Clinical Lung Cancer. 21:288-293
The Hoosier Cancer Research Network (HCRN) LUN 14-179 is a phase II trial of consolidation pembrolizumab after concurrent chemoradiation for the treatment of patients with stage III non-small-cell lung cancer (NSCLC). Time to metastatic disease or de